Daniel Teper
Founder & Chief Executive Officer NAYA Therapeutics
Daniel Teper is a serial entrepreneur and a corporate strategist who has founded, led, and advised several biopharma companies both in the US and internationally. Daniel has a proven ability to identify and execute strategic partnerships, mergers and acquisitions, and financing deals that create value for all stakeholders. Daniel holds a PharmD degree from Université Paris-Saclay, an MBA from INSEAD, and completed executive programs at Wharton and MIT.
Wednesday 16th September 2026
Chair’s Opening Remarks
8:55 am
Wednesday 16th September 2026
Panel Discussion: Why 2026 Is the Year the Gap Between Clinical Ambition & Operational Capacity Must Begin to Close
9:00 am
- Panelists will examine the state of the radiopharmaceutical supply chain in 2026: where infrastructure investment is landing, where the workforce deficit is most acute, and how the shift in isotope preferences – from the established beta emitters toward alphas and emerging candidates – is creating new pressure across every manufacturing echelon
- Discussing the compounding risks that arise as programs progress into Phase II/III, where reliance on limited isotope supply, third-party manufacturing, logistics, and fragmented coordination from CDMO through to bedside must be managed in parallel to avoid disruption to clinical delivery
- Discuss what ‘commercial readiness’ actually means for radiopharmaceuticals and why the industry’s collective definition has to evolve beyond approval to include reliable, scalable, and distributed supply at the patient level
